載入...
Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma
The addition of rituximab to cyclophosphamide, vincristine and prednisolone (CVP) for advanced follicular lymphoma increases median time to progression by 17 months. A US societal cost-effectiveness of R-CVP versus CVP is estimated for a representative 50-year-old patient. Progression-free survival...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Informa Healthcare
2008
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2430747/ https://ncbi.nlm.nih.gov/pubmed/18231908 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428190701769665 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|